JP2013501801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501801A5 JP2013501801A5 JP2012524835A JP2012524835A JP2013501801A5 JP 2013501801 A5 JP2013501801 A5 JP 2013501801A5 JP 2012524835 A JP2012524835 A JP 2012524835A JP 2012524835 A JP2012524835 A JP 2012524835A JP 2013501801 A5 JP2013501801 A5 JP 2013501801A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf antibody
- treatment
- chemotherapeutic agent
- breast cancer
- promotion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 238000011282 treatment Methods 0.000 claims 14
- 239000002246 antineoplastic agent Substances 0.000 claims 12
- 229940127089 cytotoxic agent Drugs 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 7
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229960000397 bevacizumab Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- 206010018001 Gastrointestinal perforation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000009094 second-line therapy Methods 0.000 claims 1
- 238000011519 second-line treatment Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23428109P | 2009-08-15 | 2009-08-15 | |
| US61/234,281 | 2009-08-15 | ||
| US26634309P | 2009-12-03 | 2009-12-03 | |
| US61/266,343 | 2009-12-03 | ||
| PCT/US2010/045147 WO2011022264A1 (en) | 2009-08-15 | 2010-08-11 | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240828A Division JP2016117718A (ja) | 2009-08-15 | 2015-12-10 | 以前に治療された乳癌の治療のための抗血管新生療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501801A JP2013501801A (ja) | 2013-01-17 |
| JP2013501801A5 true JP2013501801A5 (show.php) | 2013-09-19 |
| JP6088246B2 JP6088246B2 (ja) | 2017-03-01 |
Family
ID=42830354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524835A Active JP6088246B2 (ja) | 2009-08-15 | 2010-08-11 | 以前に治療された乳癌の治療のための抗血管新生療法 |
| JP2015240828A Pending JP2016117718A (ja) | 2009-08-15 | 2015-12-10 | 以前に治療された乳癌の治療のための抗血管新生療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240828A Pending JP2016117718A (ja) | 2009-08-15 | 2015-12-10 | 以前に治療された乳癌の治療のための抗血管新生療法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20110047103A1 (show.php) |
| EP (2) | EP3090758A1 (show.php) |
| JP (2) | JP6088246B2 (show.php) |
| KR (1) | KR20120107069A (show.php) |
| CN (1) | CN102573909A (show.php) |
| AR (1) | AR077848A1 (show.php) |
| AU (2) | AU2010284446A1 (show.php) |
| BR (1) | BR112012003346A2 (show.php) |
| CA (1) | CA2771086A1 (show.php) |
| CL (1) | CL2012000387A1 (show.php) |
| CO (1) | CO6612209A2 (show.php) |
| CR (1) | CR20120076A (show.php) |
| IL (1) | IL218007A0 (show.php) |
| MA (1) | MA33579B1 (show.php) |
| MX (1) | MX336476B (show.php) |
| NZ (1) | NZ598131A (show.php) |
| PH (1) | PH12012500296A1 (show.php) |
| RU (1) | RU2576027C2 (show.php) |
| SG (2) | SG178419A1 (show.php) |
| TW (2) | TW201431558A (show.php) |
| WO (1) | WO2011022264A1 (show.php) |
| ZA (1) | ZA201200998B (show.php) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| NZ783685A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| CN114191428B (zh) * | 2016-03-02 | 2024-09-24 | 卫材研究发展管理有限公司 | 基于艾日布林的抗体-药物偶联物和使用方法 |
| CA3106549A1 (en) * | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig l-asparaginase variants and methods of use |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69334351D1 (de) | 1992-02-06 | 2011-05-12 | Novartis Vaccines & Diagnostic | Biosynthetisches Bindeprotein für Tumormarker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ES2309119T3 (es) | 1992-10-28 | 2008-12-16 | Genentech, Inc. | Utilizacion de antagonistas del factor de crecimiento celular vegf. |
| EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| CN102416176A (zh) | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN100480269C (zh) | 1997-04-07 | 2009-04-22 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| PT1787999E (pt) | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
| MX353234B (es) | 1999-01-15 | 2018-01-08 | Genentech Inc | Variantes de polipeptidos con función efectora alterada. |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| AU784045B2 (en) * | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| ATE422369T1 (de) | 1999-12-24 | 2009-02-15 | Genentech Inc | Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen |
| PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20050186208A1 (en) | 2003-05-30 | 2005-08-25 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
-
2010
- 2010-08-11 WO PCT/US2010/045147 patent/WO2011022264A1/en not_active Ceased
- 2010-08-11 NZ NZ598131A patent/NZ598131A/en not_active IP Right Cessation
- 2010-08-11 PH PH1/2012/500296A patent/PH12012500296A1/en unknown
- 2010-08-11 TW TW102139989A patent/TW201431558A/zh unknown
- 2010-08-11 CA CA2771086A patent/CA2771086A1/en not_active Abandoned
- 2010-08-11 JP JP2012524835A patent/JP6088246B2/ja active Active
- 2010-08-11 CN CN2010800464523A patent/CN102573909A/zh active Pending
- 2010-08-11 SG SG2012010377A patent/SG178419A1/en unknown
- 2010-08-11 KR KR1020127006656A patent/KR20120107069A/ko not_active Abandoned
- 2010-08-11 US US12/854,711 patent/US20110047103A1/en not_active Abandoned
- 2010-08-11 BR BR112012003346A patent/BR112012003346A2/pt active Search and Examination
- 2010-08-11 EP EP16171215.3A patent/EP3090758A1/en not_active Withdrawn
- 2010-08-11 AR ARP100102939 patent/AR077848A1/es unknown
- 2010-08-11 TW TW099126812A patent/TWI451875B/zh not_active IP Right Cessation
- 2010-08-11 RU RU2012109932/15A patent/RU2576027C2/ru active
- 2010-08-11 SG SG2013073556A patent/SG194395A1/en unknown
- 2010-08-11 AU AU2010284446A patent/AU2010284446A1/en not_active Abandoned
- 2010-08-11 MX MX2012001745A patent/MX336476B/es unknown
- 2010-08-11 EP EP10747115A patent/EP2464381A1/en not_active Withdrawn
-
2012
- 2012-02-09 IL IL218007A patent/IL218007A0/en unknown
- 2012-02-10 ZA ZA2012/00998A patent/ZA201200998B/en unknown
- 2012-02-14 CR CR20120076A patent/CR20120076A/es unknown
- 2012-02-14 CL CL2012000387A patent/CL2012000387A1/es unknown
- 2012-02-20 CO CO12029506A patent/CO6612209A2/es unknown
- 2012-03-12 MA MA34681A patent/MA33579B1/fr unknown
-
2014
- 2014-11-17 US US14/543,588 patent/US20150071924A1/en not_active Abandoned
-
2015
- 2015-12-10 JP JP2015240828A patent/JP2016117718A/ja active Pending
-
2016
- 2016-05-09 AU AU2016202976A patent/AU2016202976A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520442A5 (show.php) | ||
| JP2012509889A5 (show.php) | ||
| RU2012140447A (ru) | Антиангиогенная терапия для лечения рака яичника | |
| Tahara et al. | Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) | |
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| Blum et al. | Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer | |
| JP2017514795A5 (show.php) | ||
| Kim et al. | Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial | |
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| JP2015532292A5 (show.php) | ||
| JP2013501801A5 (show.php) | ||
| JP2019506403A5 (show.php) | ||
| JP2017031160A5 (show.php) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2013173775A5 (show.php) | ||
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| JP2014515036A5 (show.php) | ||
| JP2015534577A5 (show.php) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2013543498A5 (show.php) | ||
| JP2014533279A5 (show.php) | ||
| ES2891336T3 (es) | Combinaciones y usos de las mismas | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2015517529A5 (show.php) | ||
| JP2020519675A5 (show.php) |